Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer

Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer

Despite broad anti-cancer efficacy as Toll-Like Receptor (TLR) 7/8 agonists, imidazoquinolines remain limited in use via systemic administration or in situ vaccination therapies due to inflammatory toxicity. One approach to address this challenge involves better targeting the action of imidazoquinol...

Full description

Saved in:
Bibliographic Details
Main Authors: Seyedeh A. Najibi, S. M. Al Muied Pranto, Muhammad Haroon, Amy E. Nielsen, Rock J. Mancini
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
prostate cancer
imidazoquinoline
glycoconjugate
Toll-Like Receptor
Online Access:https://www.mdpi.com/1424-8247/18/6/804
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items